• InterCure (INCR.U) and Cookies launch flagship pharmacy in Be’er Sheva, Israel
  • Cookies Be’er Sheva is the largest medical cannabis dedicated pharmacy in Israel
  • The grand opening includes festivities throughout the day; live music, food trucks, deals and special offers for all patients living in Be’er Sheva and the surrounding towns
  • Patients in the south will have access to the highly demanded Cookies GMP products such as Cake Mix, Melonatta, Fly and Ooh La La, cultivated at IntreCure’s southern facility
  • InterCure is a profitable ever-growing cannabis company outside of North America
  • InterCure (INCR.U) is sitting at C$6.53 at 12:11 pm ET

InterCure Ltd. (INCR.U) has hit a significant milestone with the grand opening of its flagship Cookies pharmacy in Be’er Sheva, known as the capital of the Negev.

The pharmacy is located in front of City Hall, in a unique building that covers an area of ​​over 1,000 square metres and is painted entirely in the recognizable Cookies baby blue.

This is perhaps one of the largest medical cannabis-dedicated pharmacies in the world.

The pharmacy grounds and staff have been equipped to serve Israel’s rapidly growing medical cannabis patient community.

Perhaps a unique feature on the grounds is the largest pharmacy safe room in Israel, with a capacity to store over a ton of medical cannabis products. Just in case the world ever experienced a shortage of cannabis.

InterCure marks the occasion in style as most others would do to celebrate their achievements.

The grand opening includes festivities throughout the day; live music, food trucks, deals and special offers for all patients living in Be’er Sheva and the surrounding towns.

Additionally, patients in the south will have access to the highly demanded Cookies GMP products such as Cake Mix, Melonatta, Fly and Ooh La La, cultivated at IntreCure’s southern facility.

InterCure’s Chief Executive Officer, Alexander Rabinovitch, briefly touched on this significant accomplishment, “Be’er Sheva is the ideal location for launching our flagship Cookies pharmacy.”

“Meeting the needs of local patients suffering from a lack of professional service and high-quality products” is a big goal of the company, and they are pleased to facilitate that.

InterCure is a profitable ever-growing cannabis company outside of North America.

Canndoc, a wholly-owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

InterCure (INCR.U) is sitting at C$6.53 at 12:11 pm ET.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.